United Kingdom· GB-APID-43184211000001100
Xofluza 80mg tablets
A baloxavir marboxil product containing baloxavir marboxil, registered in United Kingdom by Roche Products Ltd. The same ATC class is registered in 13 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Baloxavir marboxil is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AX25 (baloxavir marboxil), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 8 of them publish a price we can compare per daily dose
Baloxavir marboxil · ATC J05AX25
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Baloxavir marboxil
- Manufacturer
- Roche Products Ltd
- Country
- United Kingdom (GB)
- ATC code
- J05AX25
- ATC class
- Baloxavir marboxil
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 2
- gtin07613326059633
- gtin7613326059633
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
40 interactions on record for baloxavir marboxil.
Graded by severity as the source publishes them — 40 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Baloxavir marboxil · interactions on record
40 records
- 40 moderate
Most severe, free to view
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Magnesium hydroxideA02AA04moderate
- Kombinationen von AluminiumsalzenA02AB10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Baloxavir marboxil in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaXOFLUZAHOFFMANN-LA ROCHE LIMITED
- SwitzerlandXofluza 10 mg, Granulat zur Herstellung einer Suspension zum Einnehmen (Beutel)Roche Pharma (Schweiz) AG
- CzechiaXOFLUZARoche Registration GmbH, Grenzach-Wyhlen
- BelgiumXofluza 10 mgRoche Registration
- IcelandXofluzaRoche Registration GmbH*
- SwedenXofluza 10 mg Granulat i dospåseRoche Registration GmbH
- FinlandXofluzaRoche Registration GmbH
- NetherlandsXofluza 10 mg granulaat voor orale suspensieRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xofluza
- Liechtenstein · Xofluza
- Norway · Xofluza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e03f0814-b419-47e4-a702-651b6c10ef46 GET /v1/drugs/e03f0814-b419-47e4-a702-651b6c10ef46?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "43184211000001100",
"desc": "Xofluza 80mg tablets (Roche Products Ltd)",
"form": "Oral tablet",
"vpid": "43186211000001105",
"source": "dmd",
"vtm_id": "40338011000001101",
"strength": "80 mg",
"substance": "Baloxavir marboxil",
"ingredient": "Baloxavir marboxil",
"supplier_code": "2085201000001100"
}See everything about baloxavir marboxil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.